Introduction
We have previously suggested that the hypoxic and necrotic regions that are common in human solid tumors could be used to target cancer therapy to tumors using a genetically engineered non-pathogenic strain of the bacterial genus Clostridium. [1] [2] [3] This genus comprises a large and heterogeneous group of gram-positive, spore-forming bacteria that become vegetative and grow only in the absence (or at low levels) of oxygen. Malmgren and Flanagan 4 demonstrated that tumor-bearing mice died of tetanus within 48 h of intravenous injection of C. tetani spores, whereas non-tumor-bearing animals were unaffected. Mö se and Mö se 5, 6 later reported that a nonpathogenic clostridial strain, C. butyricum M-55, localized and germinated in solid Ehrlich tumors, causing extensive lysis without any concomitant effect on normal tissues. Such observations have been confirmed and extended by a number of investigators using tumors in mice, rats, hamsters and rabbits 7, 8 and have been followed by clinical studies with cancer patients. [9] [10] [11] Clinically, a lowgrade fever was noted 1-3 days following spore injection, and a further increase in temperature from days 5-8, coincident with lysis in the center of the tumor. While the anaerobic bacteria did not significantly alter tumor control or eradication, these clinical reports demonstrated that spores of non-pathogenic strains of clostridia can be given safely, that the spores germinate in the necrotic regions of tumors, and that lysis of the tumors can occur.
The tumor-targeted gene therapy strategy we have proposed is to inject spores of a nonpathogenic clostridial strain, genetically engineered to produce a specific protein potentially harmful to the tumor when the spores germinate. As such germination to the vegetative form will occur only in the hypoxic/necrotic regions, the protein should be produced only in the tumor. Previous studies indicated that the E. coli enzyme cytosine deaminase could be expressed in the clostridial species C. beijerinckii and could convert the non-toxic prodrug 5-fluorocytosine (5-FC) to the toxic anticancer drug 5-fluorouracil (5-FU) in vitro. In addition, intravenous injection of spores of recombinant C. beijerinckii expressing the E. coli enzyme nitroreductase (NTR) into tumor-bearing mice produced NTR protein solely in the tumors. 3 However, these past studies with genetically engineered C. beijerinkii failed to produce antitumor activity when the relevant prodrug was injected systemically (5-fluorocytosine for CD-expressing tumors and CB1954 for nitroreductase-expressing tumors). This lack of antitumor activity could have resulted from insufficient levels of prodrug-activating enzymes in the tumors due to low levels of viable clostridia in the tumors. Indeed, we found that C. beijerinkii produced only 10 5 to 10 6 bacteria per gram of tumor, 3 whereas experiments with C. oncolyticum and its closely related strain C. sporogenes gave 1-2 × 10 8 bacteria/g of tumor in experimental tumors. Unfortunately, up to the present time attempts to transform C.
sporogenes to obtain expression of enzymes capable of activating antitumor prodrugs, have presented a major technical obstacle that has not been overcome.
We now report the successful transformation of C. sporogenes using polyethylene glycol-based transfection buffer containing DNAase inhibitors. We also show that intravenous injection into tumor-bearing mice of spores of C. sporogenes containing an expression plasmid for E. coli cytosine deaminase produce tumor-specific expression of cytosine deaminase protein. Importantly, we also report significant anti-tumor efficacy of systemically injected 5-fluorocytosine following i.v. injection of these recombinant spores. These data show that anaerobic bacteria can be used to specifically target foreign proteins to solid tumors and can produce significant antitumor efficacy with little systemic toxicity.
Results

Transformation of C. sporogenes
To test the possibility that failure to transform C. sporogenes was due to extracellular secretion of endonucleases by the clostridia, we developed a protocol in which DNAase inhibitors were added to the electroporation buffer (see Materials and methods). This produced successful transformation of C. sporogenes using plasmids based on the pMTL540F shuttle vector described earlier. 2 Transformation efficiency was 100-200 transformants per g of DNA. Figure 1 shows Western blot analysis of cytosine deaminase protein expression in transformed C. sporogenes, wild-type untransformed C. sporogenes and E. coli transformed with the same vector. The transformed bacteria were found to be stable as judged by undiminished plasmid levels for up to 1 week of culture in non-selected conditions.
Activity of cytosine deaminase from C. sporogenes
We tested the function of the C. sporogenes-derived cytosine deaminase by assaying its ability to convert the nontoxic 5-FC to the toxic 5-FU. Figure 2 shows growth inhibition of SCCVII cells incubated with 5-FC alone, 5-FU alone, or the addition of cell extract from recombinant C. sporogenes added to the culture. It is apparent that the cell extract from C. sporogenes can increase the cytotoxicity of 5-FC by a factor of 10 4 bringing it to the same toxicity as 5-FU in this assay. Cell extract from C. sporogenes transformed with an empty vector did not affect the sensitivity to 5-FC, nor did cell extract from recombinant C. sporogenes affect sensitivity to 5-FU.
Choice of bacterial or yeast cytosine deaminase
As it has been reported that cytosine deaminase derived from budding yeast S. cerevisiae is more effective than that from E. coli in converting 5-fluorocytosine to 5-fluorouracil, 12 we constructed shuttle vectors for cytosine deaminase from both sources and tested them in C. sporogenes using the ability of cell extracts to render 5-FC more toxic to SCCVII cells in vitro. A clear superiority for bacterial cytosine deaminase in C. sporogenes was evident when performing the same cytotoxicity assays (data not shown). Thus, while yeast cytosine deaminase is more efficient at converting 5-FC to 5-FU in mammalian expression vectors, this is not the case with C. sporogenes.
In vivo expression of cytosine deaminase and antitumor activity
We next evaluated the expression and activity of cytosine deaminase in SCCVII tumors in mice injected i.v. with recombinant C. sporogenes. Tumor-bearing animals were injected i.v. with 10 8 spores of recombinant C. sporogenes, and 7 and 14 days later the tumors were excised and samples prepared for immunoblot analysis of cytosine deaminase and for cytosine deaminase activity in vitro as measured by the ability to convert 5-fluorocytosine to a more toxic product. Figure 3 shows that cytosine deaminase can be detected by immunoblot analysis in these tumors. To evaluate the activity to the cytosine deaminase expressed in the tumors we added the tumor extract to various concentrations of 5-FC and incubated this with SCCVII cells for 2 days. The extract from the tumors from mice injected with recombinant spores increased the cytotoxicity of 5-FC by a factor of 10 3 with no increase observed with extract from mice injected with wild-type spores (data not shown).
In further experiments we injected tumor-bearing mice with recombinant spores of C. sporogenes, removed the tumor, brain, heart, lung, liver, kidney and spleen 7 days later and performed immunoblot analysis on equal amounts of protein from each of the samples. Cytosine deaminase protein was confined to the tumor, consistent with the necessity for hypoxia/necrosis for spore germination ( Figure 4) .
We also examined the ability of the recombinant CDexpressing C. sporogenes to produce sufficient conversion of 5-FC to 5-FU in vivo to produce antitumor activity. Accordingly, tumor-bearing mice (average tumor size 150 mg) were injected with saline alone, with 5-FC alone (500 mg/kg five times per week for 2 weeks), a maximum tolerated dose of 5-FU alone (16.6 mg/kg daily 5 days per week for 2 weeks), recombinant spores alone on day 0, and recombinant spores 1 day before the daily injections of 5-FC. Injection of spores alone caused a small effect on tumor growth consistent with some tumor lysis. However, though 5-FC alone was without activity, the combination of 5-FC plus recombinant spores produced a greater growth delay than that produced by a maximum tolerated dose of 5-FU given on the same schedule ( Figure 5 ). Interestingly, in both schedules, the tumors appeared to become refractory to 5-FU after the first week of daily injections. Nonetheless, these data establish the antitumor efficacy of tumor-specific targeting of an anticancer drug delivery system using this obligate anaerobe.
Gene Therapy 
Persistence of clostridial colonization during therapy
One of the problems with transfection of tumor cells with prodrug-activating enzymes is that the transduced cells may be selectively killed. 13 This will make it very difficult to give multiple treatments and, particularly in the case of cytosine deaminase conversion of 5-FC to 5-FU, maintain adequate levels of 5-FU as a radiosensitizer during fractionated radiotherapy. 13 However, anticancer drugs are typically less active against microorganisms, so we hypothesized that this would not be a problem with the clostridial system. To test this, we measured the number of clostridial colony-forming units (c.f.u.) per gram of tumor on day 7 and day 14 after giving spore alone and giving spores with injections five times a week, of 5-FC (500 mg/kg/day). As can be seen in Figure 6 , there was no significant difference between the two groups, and levels of clostridial c.f.u. were undiminished at 14 compared with 7 days.
Discussion
The most significant problem for cancer gene therapy is delivery of the therapeutic gene to the tumor. Indeed almost all clinical trials currently being performed rely on direct intratumor injection of the vector. This is a major limitation not only for uniform distribution of the delivered gene throughout the primary tumor, but it fails to address the problem of delivery to sites of metastatic spread which may be too numerous, invisible or inaccessible for direct injection. Efforts to overcome this problem include engineering adenoviral vectors to alter their tropism for infection, 14 use of cationic liposomes with surface ligands that are specific for tumors, 15 and use of live attenuated Salmonella that can preferentially accumulate in tumors by as yet unknown mechanisms. 16, 17 In the present study, we show that intravenous injection of spores of C. sporogenes transformed to express the E. coli-derived enzyme cytosine deaminase (CD) colonize a transplanted mouse tumor, express the CD protein solely in the tumor and most importantly, produce significant antitumor efficacy from systemic administration of the prodrug 5-fluorocytosine (5-FC). Indeed we show that the antitumor efficacy of 5-FC following a single i.v. injection of recombinant spores is equivalent to, or greater than that produced by maximum tolerated doses of 5-fluorouracil (5-FU) given by the same schedule. The present results were obtained with a vector that produced the CD enzyme in a form that would not be expected to be secreted. However, earlier work with this vector transformed into C. beijerinckii demonstrated enzyme activity in the supernatent of exponentially growing bacteria, 2 presumably as a result of death of the cells. Though the anticancer efficacy in the present study could have been the result of conversion of the 5-FC to 5-FU either inside or outside the clostridial cells in the tumor, the question of the location of the enzyme could be relevant to prodrugs, such as glucuronidases that do not penetrate the cell wall.
Although we have previously demonstrated tumorspecific expression of exogenous protein following i.v. injection of recombinant spores of a clostridial species C. beijerinckii, 3 the low levels of enzymes produced negligible antitumor activity when combined with the relevant prodrug. The reason for previous failures and the present success is the efficiency of tumor colonization of the different organisms: C. beijerinckii produced only 10 5 -10 6 bacteria/g of tumor, 3 whereas C. sporogenes produced 1-2 × 10 8 bacteria/g of tumor ( Figure 6 ). This latter number is optimum: In our studies of several strains of C. sporogenes, including C. oncolyticum, 1-2 × 10 8 vegetative bacteria/g of tumor was the maximum colonization achieved (data not shown), and earlier work by Mö se and Mö se showed that strains of C. sporogenes were the most efficient at causing tumor lysis. 6 A major advantage of the clostridial delivery system is that not only is it tumor specific, it has also proved itself to be safe in humans. The lack of pathogenicity of these organisms was initially demonstrated by Mose et al (cited in Ref. 9 ) who injected themselves with spores of C. sporogenes (a strain later named C. oncolyticum), and experienced a mild fever as the only side-effect. The safety of C. oncolyticum was substantiated in clinical trials with cancer patients with a variety of solid tumors, 9, 11 and also in more recent trials in non-cancer patients with a C. beijerinckii strain. 18 Because anticancer drug delivery is typically given on multiple occasions to allow normal tissues to recover, it would be advantageous if the clostridial therapy could also be given on multiple occasions. In this respect it is helpful that the recombinant clostridia is injected as spores, which do not elicit an immune response. 18 However, it is possible that the vegetative bacteria growing in the hypoxic/necrotic areas of the tumor could be sufficiently immunogenic to eliminate the activity of more than one administration. Though we did not test multiple injections of spores, the fact that we saw no reduction in the numbers of vegetative bacteria/g of tumor between 7 and 14 days after injection is suggestive that immunogenicity will not be a problem. Also up to four repeated injections of spores of this same clostridial species has been performed over 11 weeks with successful antitumor activity in rats, 19 clearly demonstrating lack of an effective immune response. This is presumably because the regions in the center of tumors are immune privileged sites. 20 In summary, we have demonstrated that a nonpathogenic species of clostridia can be engineered to selectively express in a solid tumor an enzyme capable of activating a nontoxic prodrug to its toxic form. When these genetically engineered clostridia are introduced systemically into tumor-bearing mice, the product of the introduced enzyme gene is found only in the tumors, due to the obligate anaerobic requirement for growth of the bacteria. Further, we show that a systemically injected prodrug, which itself has no tumor activity, becomes as potent an anticancer agent as maximally tolerated doses of the drug 5-FU into which it is converted. We believe that this delivery system holds promise for gene therapy of solid tumors, because of its lack of toxicity and highly selective growth in tumors.
Materials and methods
Mice and tumors
We used SCCVII tumors transplanted into their syngeneic host C3H/Km mice in these studies. All the mice were bred and housed under pathogen-free conditions in the AAALAC-accredited Stanford University Research Animal Facility, and the experiments were conducted according to the guidelines and directives set out by the Stanford University Administrative Panel on Laboratory Animal Care.
Tumors were produced from SCCVII cells in monolayer cultures by inoculating single cell suspensions intradermally on to the back of each mouse 2 cm from the tail. Descriptions of the derivation, characteristics and handling of the tumors have been published previously. 21 Experiments were performed approximately 2 weeks later when the tumor volume was 100-150 mm 3 . The efficacy of the various treatments was determined by measuring tumor volume three times weekly.
Transformation of C. sporogenes
Expression of heterologous genes in the E. coli-clostridia shuttle vector pMTL540F has previously been found to be optimal when the gene is inserted in at the NdeI site of the MCS, which is immediately adjacent to the promoter. 22 Since the E. coli cytosine deaminase gene contains an internal NdeI site, the forward primer was designed to contain the AseI restriction site, which generates ends complimentary to those produced by NdeI. The reverse primer contained a restriction site for XbaI, allowing directional cloning of the PCR product. The gene encoding cytosine deaminase was amplified from HB101 E. coli genomic DNA by PCR and a product of the predicted size was gel-purified, digested with AseI and XbaI, and ligated to NdeI/XbaI digested vector DNA. 2 Ligation products were transformed into competent E. coli and plasmid minipreps performed by standard procedures. We confirmed the absence of PCR-induced mutations in the CD gene by sequencing before largescale plasmid preparation.
The electroporation technique used was based on published methods, 23 with modifications. After harvesting C. sporogenes, the cells were washed in 10 ml electroporation buffer (10% polyethylene glycol containing 1 mg/ml polyanetholesulfonic acid). They were then centrifuged and resuspended in 3 ml cold electroporation buffer containing additional DNAase inhibitor (aurintricarboxylic acid in 0.1 mg/ml). 1-5g DNA was then placed into a 0.2-cm inter-electrode distance cuvette, 0.4 ml cells added and pulsed once at 1.25 kV, 100 Ohms, 25 FD.
Growth and sporulation of C. sporogenes C. sporogenes were grown in an anaerobic chamber in 2× TPGY media (trypticase peptone, 2%; peptone, 0.5%; glucose, 0.1%; yeast extract, 0.5%; cysteine HCl, 0.1%; agar, 2%). Medium was brought quickly into the anaerobic chamber after autoclaving (which drives off the dissolved oxygen) and was equilibrated with the chamber atmosphere for 24 h before use. The bacteria were normally grown at 37°C unless sporulation cultures were in progress in the same incubator, in which case, the temperature was reduced to 30°C. The bacteria grow equally well at these two temperatures with a doubling time of 45-60 min.
Gene Therapy Sporulation was induced as described previously. 3 Spores were stored at Ϫ20°C until needed for animal injection. Before injection, the spores were washed three times with PBS and subjected to a 75°C 20-min heat shock (1 ml volume). The mice were injected intravenously with 0.1 ml volume of a suspension of 10 9 spores/ml in PBS.
Immunoblot analysis for cytosine deaminase
Tumor homogenates were lysed by 3 × 20-s sonications with a Virsonic 300 sonicator (Virtis, Gardiner, NY, USA) with the samples being kept on ice for at least 2 min between each sonication. Protein concentrations were determined by a Bradford assay with bovine serum albumin as a standard. Lysed samples were run on SDS-PAGE mini-gels. Proteins were transferred to nitrocellulose (Hybond ECL; Amersham, Arlington Heights, IL, USA), and gels stained with Coomassie brilliant blue to check for uniform transfer of proteins. Nitrocellulose membranes were blocked with 5% milk in Tris-buffered saline overnight at 4°C and then incubated at room temperature for 1 h with a 1:20 000 dilution of an anti-CD polyclonal rabbit serum obtained from Dr Joannes Gebert (Chirurgishe Universitatsklinik, University of Heidelberg, Germany). Membranes were washed in Tris-buffered saline and incubated for 1 h at room temperature with horseradish peroxidase-conjugated goat anti-rabbit IgG (Amersham) and autoradiographed with a chemoluminescence system according to the manufacturer's instructions (ECL detection system, Amersham).
